PharmaPoint Rheumatoid Arthritis - Drug Forecast and Market PharmaPoint Rheumatoid Arthritis - Drug Market | Page 8

8.3.8 Baricitinib 259
8.3.9 Peficitinib 269
8.3.10 Decernotinib 275
8.3.11 Filgotinib 281
8.3.12 Masitinib 287
8.3.13 RAVAX 294
8.4 Other Drugs in Development 299

9 Current and Future Players 302
9.1 Trends in Corporate Strategy 305
9.2 Company Profiles 306
9.2.1 AbbVie 306
9.2.2 Pfizer 308
9.2.3 Amgen 311
Browse Complete Summary Click Here @ http://www.radiantinsights.com/research/pharmapointrheumatoid-arthritis-global-drug-forecast-and-market-analysis-to-2023
9.2.4 Johnson & Johnson 314
9.2.5 Eli Lilly 316
9.2.6 Bristol-Myers Squibb 318
9.2.7 UCB 320
9.2.8 Roche 321
9.2.9 GlaxoSmithKline 323
9.2.10 Novartis 325
9.2.11 Sanofi 327
9.2.12 AstraZeneca- MedImmune 329
9.2.13 Astellas 331